M&A Deal Summary

Amdipharm Mercury - AMCo. Acquires Focus Pharmaceuticals

On October 1, 2010, Amdipharm Mercury - AMCo. acquired life science company Focus Pharmaceuticals from Mobeus Equity Partners for 50M GBP

Acquisition Highlights
  • This is Amdipharm Mercury - AMCo.’s 1st transaction in the Life Science sector.
  • This is Amdipharm Mercury - AMCo.’s largest (disclosed) transaction.
  • This is Amdipharm Mercury - AMCo.’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2010-10-01
Target Focus Pharmaceuticals
Sector Life Science
Buyer(s) Amdipharm Mercury - AMCo.
Sellers(s) Mobeus Equity Partners
Deal Type Add-on Acquisition
Deal Value 50M GBP

Target

Focus Pharmaceuticals

London, United Kingdom
Focus Pharmaceuticals Ltd is a generic pharmaceutical company specializing in bringing new generic products to market in the UK.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amdipharm Mercury - AMCo.

Croydon, United Kingdom
Category Company
Sector Life Science
DESCRIPTION

Amdipharm Mercury (AMCo) is an international speciality pharmaceuticals company delivering high quality medicines with a customer focus in 112 territories.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 3
Country (United Kingdom) 1 of 1
Year (2010) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-12-06 Abcur AB

Sweden

Abcur AB is a Swedish based pharmaceutical company focusing on development, registration and marketing of specialized pharmaceutical products. Our strive is to make necessary pharmaceutical products available in the Nordic area. This is done by a close cooperation with the medical care.

Buy -

Seller(S) 1

SELLER

Mobeus Equity Partners

London, United Kingdom

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2004
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

Mobeus Equity Partners is a generalist investor in UK-based companies. Mobeus looks to invest between £2 and £20 million in a variety of transaction situations. These include MBOs, secondary buyouts, debt financings, shareholder liquidity needs, and recapitalizations. Mobeus generally targets high growth, profitable (£1 to £5 million) businesses with sustainable competitive advantages. Mobeus is based in London.

DEAL STATS #
Overall 11 of 48
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 6 of 26
Country (United Kingdom) 11 of 47
Year (2010) 3 of 3
Size (of disclosed) 3 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-10-01 SEC Life Sciences

London, United Kingdom

SEC Life Sciences is a specialist recruitment and resourcing service provider to a wide range of customers throughout Europe. SEC Life Sciences was founded in 1992 and is based in London, United Kingdom.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-11-21 Bourn Hall Clinic

Cambridge, United Kingdom

Bourn Bioscience Ltd. is an independent fertility provider that offers fertility treatments to self-funding and NHS patients in our clinics in Cambridge, Colchester, Norwich, King's Lynn, Peterborough, and Wickford. Bourn Bioscience was established in 1980 and is based in Cambridge, United Kingdom.

Buy -
Mergr

Product

Company

Legal